Edition:
United States

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

2.39USD
14 Dec 2017
Change (% chg)

$-0.10 (-4.02%)
Prev Close
$2.49
Open
$2.49
Day's High
$2.64
Day's Low
$2.36
Volume
61,007
Avg. Vol
72,117
52-wk High
$3.67
52-wk Low
$0.88

Chart for

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)

Overall

Beta: 2.57
Market Cap(Mil.): $85.18
Shares Outstanding(Mil.): 35.64
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

Galectin slumps after NASH drug misses main goal of mid-stage trial

Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.

Dec 05 2017

UPDATE 1-Galectin slumps after NASH drug misses main goal of mid-stage trial

Dec 5 Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.

Dec 05 2017

BRIEF-Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results

* Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results in treatment of advanced melanoma from a phase 1b clinical trial Source text for Eikon: Further company coverage:

Nov 13 2017

BRIEF-Galectin Therapeutics posts qtrly loss per share $0.13‍​

* Galectin Therapeutics Inc - ‍Top line results of NASH-CX phase 2B clinical trial expected to be announced in early December 2017​

Nov 07 2017

BRIEF-Galectin Therapeutics Q2 loss per share $0.14

* Galectin Therapeutics reports 2017 second quarter financial results and provides business update

Aug 14 2017

Competitors

Earnings vs. Estimates